1[1]Greenlee RT,Hill-Harmon MB,Murray T,et al.Cancer statistics,2001.CA Cancer J Clin,2001,51:15-36.
2[2]Wingo PA,Cardinez CJ,Landis SH,Long-term trends in cancer mortality in the United States,1930-1998,Cancer 2003,97:3133-3275.
3[3]de Cremoux P,Coste J,Sastre-Garau X,et al.Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening.A study by the French Society of Clinical Cytology.Am J Clin Pathol,2003,120:492-499.
4[4]Castle PE,Sideri M,Jeronimo J,et al.Risk assessment to guide the prevention of cervical cancer,Am J Obstet Gynecol,2007,197:351-356.
5[5]Nanda K,McCrory DC,Myers ER,et al.Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities:a systematic review.Ann Intern Med,2000,132:810-819.
6[6]Schiffman M,Solomon D.Findings to date from the ASCUS-LSIL Triage Study (ALTS).Arch Pathol Lab Med,2003,127:946-949.
7[7]Pan Q,Belinson JL,Li L,et al.A thin-layer,liquid-based pap test for mass screening in an area of China with a high incidence of cervical carcinoma.A cross-sectional,comparative study.Acta Cytol,2003,47:45-50.
8[8]Belinson JL,Pan QJ,Biscotti C,et al.Primary screening with liquid-based cytology in an unscreened population in rural China,with an emphasis on reprocessing unsatisfactory samples.Acta Cytol,2002,46:470-474.
9[9]Nielsen ML.Cytopathology laboratory improvement programs of the College of American Pathologists:Laboratory Accreditation Program (CAP LAP) and Performance Improvement Program in Cervicovaginal Cytology (CAP PAP).Arch Pathol Lab Med,1997,121:256-259.
10[10]Nielsen ML,Davey DD,Kline TS.Specimen adequacy evaluation in gynecologic cytopathology:current laboratory practice in the College of American Pathologists Interlaboratory Comparison Program and tentative guidelines for future practice,Diagn Cytopathol,1993,9:394-403.
